loading
Kiora Pharmaceuticals Inc stock is traded at $3.25, with a volume of 6,964. It is down -0.31% in the last 24 hours and down -9.72% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.26
Open:
$3.25
24h Volume:
6,964
Relative Volume:
0.17
Market Cap:
$9.75M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.2265
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-1.52%
1M Performance:
-9.72%
6M Performance:
-11.20%
1Y Performance:
-43.76%
1-Day Range:
Value
$3.19
$3.30
1-Week Range:
Value
$3.07
$3.53
52-Week Range:
Value
$2.91
$6.48

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name
Name
Kiora Pharmaceuticals Inc
Name
Phone
781-788-8869
Name
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Name
Employee
12
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
KPRX's Discussions on Twitter

Compare KPRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KPRX
Kiora Pharmaceuticals Inc
3.25 9.75M 0 2.81M 7.14M -14.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

pulisher
Mar 12, 2025

Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan

Mar 12, 2025
pulisher
Mar 02, 2025

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World

Mar 02, 2025
pulisher
Feb 24, 2025

Kiora Pharmaceuticals secures new patent for KIO-104 - MSN

Feb 24, 2025
pulisher
Feb 18, 2025

Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World

Feb 18, 2025
pulisher
Feb 18, 2025

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World

Feb 18, 2025
pulisher
Feb 14, 2025

CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga

Feb 14, 2025
pulisher
Feb 14, 2025

Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria

Feb 14, 2025
pulisher
Feb 13, 2025

Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 - StockTitan

Feb 13, 2025
pulisher
Feb 13, 2025

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile

Feb 13, 2025
pulisher
Feb 11, 2025

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile

Feb 11, 2025
pulisher
Feb 05, 2025

Retinitis Pigmentosa Treatment Market Industry Growth - openPR

Feb 05, 2025
pulisher
Jan 28, 2025

US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St

Jan 28, 2025
pulisher
Jan 24, 2025

Promising US Penny Stocks To Consider In January 2025 - Simply Wall St

Jan 24, 2025
pulisher
Jan 23, 2025

3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance

Jan 23, 2025
pulisher
Jan 21, 2025

January 2025's Top US Penny Stocks To Consider - Yahoo Finance

Jan 21, 2025
pulisher
Jan 20, 2025

Kiora Pharmaceuticals, Inc. Announces Promotion of Melissa Tosca to Chief Financial Officer - Marketscreener.com

Jan 20, 2025
pulisher
Jan 15, 2025

Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

3 US Penny Stocks With Market Caps Under $200M - Simply Wall St

Jan 14, 2025
pulisher
Jan 13, 2025

US Penny Stocks: 3 Picks With Market Caps Below $400M - Yahoo Finance

Jan 13, 2025
pulisher
Jan 08, 2025

3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance

Jan 08, 2025
pulisher
Jan 06, 2025

Cerus And 2 Other US Penny Stocks With Promising Potential - Yahoo Finance

Jan 06, 2025
pulisher
Jan 03, 2025

3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St

Jan 03, 2025
pulisher
Jan 02, 2025

US Penny Stocks To Watch In January 2025 - Yahoo Finance

Jan 02, 2025
pulisher
Jan 01, 2025

3 Promising US Penny Stocks With Market Caps Under $80M - Simply Wall St

Jan 01, 2025
pulisher
Dec 24, 2024

Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World

Dec 24, 2024
pulisher
Dec 09, 2024

Retinitis Pigmentosa Treatment Market Report: Detailed - openPR

Dec 09, 2024
pulisher
Dec 06, 2024

Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail

Dec 06, 2024
pulisher
Dec 06, 2024

Persistent Epithelial Defect Market Statistics Expected - openPR

Dec 06, 2024
pulisher
Dec 05, 2024

Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR

Dec 05, 2024
pulisher
Nov 29, 2024

Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use - Marketscreener.com

Nov 29, 2024
pulisher
Nov 19, 2024

Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.

Nov 19, 2024
pulisher
Nov 19, 2024

Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire

Nov 19, 2024
pulisher
Nov 15, 2024

What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World

Nov 15, 2024
pulisher
Nov 15, 2024

ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK

Nov 12, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile

Nov 08, 2024
pulisher
Oct 30, 2024

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance

Oct 29, 2024
pulisher
Sep 25, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN

Sep 25, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com

Sep 12, 2024
pulisher
Aug 09, 2024

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance

Aug 09, 2024
pulisher
Jul 30, 2024

Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe

Jul 30, 2024

Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):